TRACK BRANDS ON AI
Monitor your brand, company, or product's online reputation in AI responses
Searching...
Loading...
It's taking longer than usual, we might be experiencing higher load.
Give it a few more seconds or try again in a moment.
Give it a few more seconds or try again in a moment.
Searching...
Loading...
What does AI know about Cara Therapeutics Inc?
What does OpenAI free version (gpt-3.5-turbo) know about Cara Therapeutics Inc?
| Last request | 30.05.2024
(There is a high chance that below response is an AI hallucination) |
| Well Known | No |
| Description | Biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus |
| Most Notable Achievements | Successful clinical trials for their lead product candidate |
| The Most Negative Fact | Limited product portfolio |
| Competition | None |
| Share with friends |
Register your email below to unlock features!
Don't like the AI answers? Who can help me Change them?
What does OpenAI paid version (gpt-4) know about Cara Therapeutics Inc?
| Request date | |
| Well Known | No |
| Description | Cara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors. |
| Most Notable Achievements | The company has a promising pipeline of drugs for treating pruritus and pain, with its lead candidate, Korsuva, showing positive results in clinical trials. |
| The Most Negative Fact | The company is still in the clinical stage and has not yet generated any revenue from product sales. |
| Competition | |
| Share with friends |
What does Google AI (PaLM) know about Cara Therapeutics Inc?
| Last request | 30.05.2024 |
| Well Known | no |
| Description | Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel, proprietary, small molecule therapeutics for the treatment of pain. |
| Most Notable Achievements | The company's lead product candidate, CR845, is a novel, oral, once-daily, peripherally restricted, G protein-coupled receptor agonist that is in Phase 2 clinical development for the treatment of moderate to severe acute pain. |
| The Most Negative Fact | The company has a limited product pipeline and is dependent on the success of its lead product candidate, CR845. |
| Competition | None |
What does Microsoft Bing AI know about Cara Therapeutics Inc?
| Well Known | No |
| Description | lztlthunpcdiiaadu ronusc eltce aynelpidnvmfci cd ansi e oteegee lnnicwg ioespttmrcoimo iol r m aaamaapn vin nihcBsuad eiiprgeea edo |
| Most Notable Achievements | csset ifcdf u ineuolrcd a isaocdt ptrtnca urellaceaiiSrdlhl |
| The Most Negative Fact | tuce irom dtprfot dioiLlop |
| Competition | enNo |
Register your email below to unlock features!
Looks like you haven't registered an account yet?
Just search for a brand, person or top-list BELOW and register your email on the search results page:
